Roche's Breast-Cancer Drug Could Face Tough Upcoming Trial -- Market Talk

Dow Jones10-20

1255 GMT - The efficacy of Roche's experimental breast-cancer drug Giredestrant was driven by patients whose tumors carried estrogen receptor 1 mutations--a form resistant to standard hormone drugs--, UBS analysts write. This might hurt its chances of success in an upcoming trial in which there will be fewer of these mutations, UBS says. Trial results also showed a higher incidence of one common side effect--slow heart rate--though the overall safety profile was acceptable, the analysts say, adding that no instances of eye toxicity were seen--another common side effect of the already-approved standard-of-care treatment--. Moreover, there was an improvement across the general population in response rate and duration, the analysts add. UBS expects peak annual sales of around $500 million and assigns a 60% probability of approval. Shares fall 1.9%. (william.gray@wsj.com)

(END) Dow Jones Newswires

October 20, 2025 08:56 ET (12:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2576854034?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576854034","market":"hk","top_or_hot":-1,"title":"Roche's Breast-Cancer Drug Could Face Tough Upcoming Trial -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1255 GMT - The efficacy of Roche's experimental breast-cancer drug Giredestrant was driven by patients whose tumors carried estrogen receptor 1 mutations--a form resistant to standard hormone drugs--, UBS analysts write. This might hurt its chances of success in an upcoming trial in which there will be fewer of these mutations, UBS says. Trial results also showed a higher incidence of one common side effect--slow heart rate--though the overall safety profile was acceptable, the analysts say, adding that no instances of eye toxicity were seen--another common side effect of the already-approved standard-of-care treatment--. Moreover, there was an improvement across the general population in response rate and duration, the analysts add. UBS expects peak annual sales of around $500 million and assigns a 60% probability of approval. Shares fall 1.9%. (william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 08:56 ET (12:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Breast-Cancer Drug Could Face Tough Upcoming Trial -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Breast-Cancer Drug Could Face Tough Upcoming Trial -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-20 20:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1255 GMT - The efficacy of Roche's experimental breast-cancer drug Giredestrant was driven by patients whose tumors carried estrogen receptor 1 mutations--a form resistant to standard hormone drugs--, UBS analysts write. This might hurt its chances of success in an upcoming trial in which there will be fewer of these mutations, UBS says. Trial results also showed a higher incidence of one common side effect--slow heart rate--though the overall safety profile was acceptable, the analysts say, adding that no instances of eye toxicity were seen--another common side effect of the already-approved standard-of-care treatment--. Moreover, there was an improvement across the general population in response rate and duration, the analysts add. UBS expects peak annual sales of around $500 million and assigns a 60% probability of approval. Shares fall 1.9%. (william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 08:56 ET (12:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576854034","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576854034","pubTimestamp":1760964960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1255 GMT - The efficacy of Roche's experimental breast-cancer drug Giredestrant was driven by patients whose tumors carried estrogen receptor 1 mutations--a form resistant to standard hormone drugs--, UBS analysts write. This might hurt its chances of success in an upcoming trial in which there will be fewer of these mutations, UBS says. Trial results also showed a higher incidence of one common side effect--slow heart rate--though the overall safety profile was acceptable, the analysts say, adding that no instances of eye toxicity were seen--another common side effect of the already-approved standard-of-care treatment--. Moreover, there was an improvement across the general population in response rate and duration, the analysts add. UBS expects peak annual sales of around $500 million and assigns a 60% probability of approval. Shares fall 1.9%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","BK4007":"制药","RHHBY":"罗氏控股"},"translate_title":"罗氏的乳腺癌药物可能面临即将到来的艰难试验——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9},"content_text":"1255 GMT - The efficacy of Roche's experimental breast-cancer drug Giredestrant was driven by patients whose tumors carried estrogen receptor 1 mutations--a form resistant to standard hormone drugs--, UBS analysts write. This might hurt its chances of success in an upcoming trial in which there will be fewer of these mutations, UBS says. Trial results also showed a higher incidence of one common side effect--slow heart rate--though the overall safety profile was acceptable, the analysts say, adding that no instances of eye toxicity were seen--another common side effect of the already-approved standard-of-care treatment--. Moreover, there was an improvement across the general population in response rate and duration, the analysts add. UBS expects peak annual sales of around $500 million and assigns a 60% probability of approval. Shares fall 1.9%. (william.gray@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 08:56 ET (12:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576854034","isCrawlerRequest":true}